<DOC>
	<DOCNO>NCT00150748</DOCNO>
	<brief_summary>An open-label , follow-up study evaluate safety efficacy levetiracetam ( LEV ) , child ( â‰¥ 4 year old ) , adolescent adult suffer primary generalized seizure .</brief_summary>
	<brief_title>Long Term Follow Treatment With Levetiracetam Subjects 4 Years Older With Generalized Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy , Generalized</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Male female child , adolescent adult complete final visit previous study levetiracetam ( LEV ) Subjects were/are suffer primary generalize ( type II ) epileptic seizure Subjects Investigator believe reasonable benefit ( efficacy tolerability ) longterm administration LEV may expect Known clinically significant acute chronic illness , example : cardiac , renal hepatic dysfunction , etc. , may impair reliable participation trial necessitate use medication allow protocol Concomitant use drug possible central nervous system effect unless stable dose Concomitant use drug ( hormonal treatment subject 's normal antiepileptic drug ( AEDs ) may influence metabolism concomitant AED ( ) , except dose stable entry study sufficient length time</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Generalized Epilepsy , Primary Generalized Seizures</keyword>
	<keyword>Keppra , Levetiracetam</keyword>
</DOC>